Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BGM BGM Group	$10.95 +11.2%	$12.08	$5.26 ▼ $17.17	$957.64M	1.29	69,625 shs	99,837 shs
ELVN Enliven Therapeutics	$21.95 -1.8%	$20.32	$13.30 ▼ $30.03	$1.10B	0.83	509,380 shs	222,821 shs
GPCR Structure Therapeutics	$18.27 +0.6%	$21.25	$13.22 ▼ $45.37	$1.04B	-1.87	660,986 shs	525,137 shs
MREO Mereo BioPharma Group	$1.74 -6.7%	$2.41	$1.57 ▼ $5.02	$296.54M	0.46	4.33 million shs	1.88 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BGM BGM Group	-1.89%	+3.68%	-24.92%	-10.70%	+984,999,900.00%
ELVN Enliven Therapeutics	+3.66%	+4.15%	+10.15%	+22.13%	-9.07%
GPCR Structure Therapeutics	-0.16%	-7.35%	-17.83%	-23.21%	-49.47%
MREO Mereo BioPharma Group	+5.97%	+6.57%	-31.93%	-26.57%	-54.84%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BGM BGM Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	2.722 of 5 stars	3.5	2.0	0.0	0.0	1.9	4.2	0.0
GPCR Structure Therapeutics	3.0157 of 5 stars	3.5	3.0	0.0	0.0	3.2	1.7	0.6
MREO Mereo BioPharma Group	1.8598 of 5 stars	3.6	1.0	0.0	0.0	2.2	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BGM BGM Group	0.00	N/A	N/A	N/A
ELVN Enliven Therapeutics	3.00	Buy	$41.20	87.70% Upside
GPCR Structure Therapeutics	3.00	Buy	$76.17	316.89% Upside
MREO Mereo BioPharma Group	3.20	Buy	$7.20	313.79% Upside

Current Analyst Ratings Breakdown

Latest MREO, ELVN, GPCR, and BGM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$7.00 ➝ $5.00
7/2/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $48.00
6/23/2025	GPCR Structure Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$65.00
6/23/2025	GPCR Structure Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$89.00
6/16/2025	ELVN Enliven Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00 ➝ $52.00
6/16/2025	ELVN Enliven Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$37.00
5/16/2025	ELVN Enliven Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $27.00
5/15/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00
5/13/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
5/12/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $75.00
5/2/2025	GPCR Structure Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00

(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BGM BGM Group	$25.10M	42.41	N/A	N/A	$7.34 per share	1.49
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$6.34 per share	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$15.10 per share	N/A
MREO Mereo BioPharma Group	$10M	27.67	N/A	N/A	$0.39 per share	4.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BGM BGM Group	-$1.44M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	-$89.02M	-$1.92	N/A	N/A	N/A	N/A	-31.84%	-30.09%	8/12/2025 (Estimated)
GPCR Structure Therapeutics	-$122.53M	-$0.87	N/A	N/A	N/A	N/A	-16.35%	-15.71%	8/6/2025 (Estimated)
MREO Mereo BioPharma Group	-$43.25M	-$0.07	N/A	N/A	N/A	N/A	-69.33%	-57.27%	8/12/2025 (Estimated)

Latest MREO, ELVN, GPCR, and BGM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	GPCR Structure Therapeutics	-$0.28	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	ELVN Enliven Therapeutics	-$0.54	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	MREO Mereo BioPharma Group	-$0.01	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	ELVN Enliven Therapeutics	-$0.51	-$0.57	-$0.06	-$0.57	N/A	N/A
5/13/2025	Q1 2025	MREO Mereo BioPharma Group	-$0.01	-$0.02	-$0.01	-$0.02	$72.50 million	N/A
5/8/2025	Q1 2025	GPCR Structure Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BGM BGM Group	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BGM BGM Group	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	21.07	21.06
GPCR Structure Therapeutics	N/A	23.29	23.29
MREO Mereo BioPharma Group	N/A	8.92	8.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BGM BGM Group	N/A
ELVN Enliven Therapeutics	95.08%
GPCR Structure Therapeutics	91.78%
MREO Mereo BioPharma Group	62.83%

Insider Ownership

Company	Insider Ownership
BGM BGM Group	58.66%
ELVN Enliven Therapeutics	25.90%
GPCR Structure Therapeutics	9.43%
MREO Mereo BioPharma Group	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BGM BGM Group	298	97.22 million	40.19 million	N/A
ELVN Enliven Therapeutics	50	49.07 million	36.36 million	Optionable
GPCR Structure Therapeutics	136	57.34 million	51.94 million	Optionable
MREO Mereo BioPharma Group	40	159.00 million	150.26 million	Optionable

MREO, ELVN, GPCR, and BGM Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

July 22 at 10:00 AM | prnewswire.com

Mereo BioPharma Group (NASDAQ:MREO) Cut to Sell at Wall Street Zen

July 21 at 3:59 AM | americanbankingnews.com

Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO) Receives Consensus Rating of "Buy" from Brokerages

July 19, 2025 | americanbankingnews.com

Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO) Given Consensus Rating of "Buy" by Brokerages

July 19, 2025 | marketbeat.com

Mereo BioPharma Group (NASDAQ:MREO) Lowered to Sell Rating by Wall Street Zen

July 19, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

July 17, 2025 | prnewswire.com

Mereo BioPharma Group Stock Short Interest Report | NASDAQ:MREO - Benzinga

July 11, 2025 | benzinga.com

Mereo BioPharma Group Analyst Ratings and Price Targets | NASDAQ:MREO ...

July 11, 2025 | benzinga.com

Mereo BioPharma: Buy Rating Despite No Early Study Completion Of Setrusumab For OI

July 10, 2025 | seekingalpha.com

RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End

July 10, 2025 | zacks.com

Ultragenyx, Mereo Plummet After Late-Stage Trial for Rare Genetic Disorder Appears To Fall Short

July 10, 2025 | biospace.comB

Ultragenyx, Mereo Hammered For Their Surprise Miss In Brittle Bone Disease

July 10, 2025 | investors.com

Mereo BioPharma Group (NASDAQ:MREO) Price Target Lowered to $5.00 at Needham & Company LLC

July 10, 2025 | marketbeat.com

Ultragenyx Pharmaceutical Inc.: Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis

July 10, 2025 | finanznachrichten.de

Mereo BioPharma Group plc (MREO) - Yahoo Finance

July 9, 2025 | finance.yahoo.com

Ultragenyx, Mereo Slide as Drug Study Progresses to Final Analysis

July 9, 2025 | marketwatch.com

MREO | Mereo BioPharma Group PLC ADR - Wall Street Journal

June 29, 2025 | wsj.com

Mereo rebrands as Cedar Trace

June 10, 2025 | royalgazette.comR

Why Mereo BioPharma Group plc’s (MREO) Stock Is Down 5.63%

May 16, 2025 | aaii.comA

We're Not Very Worried About Mereo BioPharma Group's (NASDAQ:MREO) Cash Burn Rate

May 15, 2025 | finance.yahoo.com

Mereo BioPharma Group plc: Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights

May 13, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

MREO, ELVN, GPCR, and BGM Company Descriptions

BGM Group NASDAQ:BGM

$10.95 +1.10 (+11.17%)

Closing price 04:00 PM Eastern

Extended Trading

$10.96 +0.01 (+0.05%)

As of 05:09 PM Eastern

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Enliven Therapeutics NASDAQ:ELVN

$21.95 -0.40 (-1.79%)

Closing price 04:00 PM Eastern

Extended Trading

$21.86 -0.09 (-0.39%)

As of 04:04 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Structure Therapeutics NASDAQ:GPCR

$18.27 +0.11 (+0.61%)

Closing price 04:00 PM Eastern

Extended Trading

$18.24 -0.03 (-0.19%)

As of 06:50 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Mereo BioPharma Group NASDAQ:MREO

$1.74 -0.13 (-6.70%)

Closing price 04:00 PM Eastern

Extended Trading

$1.75 +0.01 (+0.57%)

As of 07:43 PM Eastern

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time